Search - tctmd.com

Displaying 61 - 80 of 112

Sort: Relevancy | Date

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

March 27, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

February 17, 2023

Vast Majority of HFrEF Patients Eligible for Vericiguat

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

February 08, 2023

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

January 13, 2023

Even When Eligible, Not All Acute HF Patients Get GDMT

News Daily News

Even When Eligible, Not All Acute HF Patients Get GDMT

January 11, 2023

Top Heart Failure News of 2022

News Daily News

Top Heart Failure News of 2022

January 04, 2023

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

December 08, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

June 23, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

May 22, 2022

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 05, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

April 20, 2022

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

News Daily News

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

March 31, 2022

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

March 22, 2022

FDA Approves Empagliflozin for Treatment of HFpEF

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.